In a key update to its COVID-19 vaccination strategy, the U.S. Food and Drug Administration (FDA) has recommended that pharmaceutical manufacturers update their COVID-19 vaccines to target the LP.8.1 strain, the most dominant variant currently circulating in the United States.
The recommendation, announced Thursday evening, marks a departure from the guidance given earlier the same day by the FDA’s vaccine advisory committee, which had supported retaining the existing vaccine strains. However, the panel also deemed LP.8.1 a viable alternative. According to recent data, the LP.8.1 strain accounts for approximately 75% of new COVID-19 cases across the country.
Stronger Immune Response Observed
Early findings from both Pfizer and Moderna suggest that vaccines targeting LP.8.1 trigger a slightly stronger immune response against current variants compared to vaccines based on older strains such as JN.1 or its subvariant KP.2. LP.8.1 itself is a descendant of JN.1.
Despite the promising data, the FDA’s preference for the LP.8.1 formulation introduces new regulatory complexities. Under updated FDA rules, any vaccine that is modified to target a new strain will require placebo-controlled clinical trials, a process that could delay the rollout of vaccines to the general population.
Limited Availability for the General Public
As a result of the new policy, updated COVID-19 vaccines may be available this fall only to high-risk groups, including adults aged 65 and older and individuals with underlying health conditions. These groups are exempt from the clinical trial requirement.
The list of qualifying conditions is broad, even including lifestyle factors such as physical inactivity. Federal health officials estimate that more than 100 million Americans would still qualify for the vaccine under these exemptions.
Dr. Jesse Goodman, former FDA chief scientist and current professor of medicine at Georgetown University, expressed concern that the new trial requirements could hinder access to vaccines for otherwise healthy individuals who still wish to be vaccinated. “The trial requirement will delay and impede access for many people,” he said.
Unanswered Questions from the FDA
During a Senate committee hearing on Thursday, FDA Commissioner Dr. Marty Makary estimated that the required trials could take about a year. However, many questions remain unanswered, including how many participants will be needed and whether strain updates alone automatically trigger the trial mandate.
FDA officials did not provide direct responses to several questions posed during the hearing, either stating the matters were still under discussion or declining to address them.
The agency’s announcement leaves some flexibility for vaccine makers, stating that it would “prefer” they update to LP.8.1 — language that could allow some companies to continue using current formulations.
Industry Response and Insurance Concerns
Pfizer issued a statement on Thursday confirming it is ready to begin producing a 2025–2026 formulation based on FDA recommendations as soon as approval is granted. Moderna and Novavax have not yet commented.
Questions also remain about how health insurance providers will handle coverage for individuals who do not qualify under the current exemption criteria. Pfizer and Moderna are currently listing their COVID-19 vaccines at prices of up to $150 per dose. Novavax’s vaccine, which was fully approved earlier this month, has not yet been priced publicly.
A spokesperson from America’s Health Insurance Plans, a major industry group, said insurance providers are committed to offering affordable access to preventive healthcare, including vaccinations. “We will continue to monitor CDC and ACIP guidance as it becomes available,” the group said in a statement.
A Shift in Vaccine Policy
Emily Hilliard, spokesperson for the Department of Health and Human Services, noted that the country has entered a new phase in its response to the virus. “The COVID-19 public health emergency has officially ended,” she said, “and the days of automatically approving updated boosters without new clinical data are over.”
While the FDA’s direction signals a more cautious regulatory approach, public health experts caution that evolving variants and limited data make it difficult to predict which strains will dominate in the months ahead. For now, the LP.8.1 strain remains the main target, and for millions of Americans, access to protection this fall may depend on eligibility status and the speed of clinical trial outcomes.
Explore more entrepreneurial insights and success stories at Inspirepreneur, your go-to magazine for business innovation and leadership.
